Glaxo accused of pay-for-delay deal

Press Association
GSK
GSK

Drugs giant GlaxoSmithKline has been accused by the competition watchdog of paying off firms to delay the launch of cheap versions of its antidepressant treatment in a move that denied the NHS "significant" cost savings.


The Office of Fair Trading (OFT) is alleging that Glaxo offered "substantial" payments to Alpharma, Generics and Norton Healthcare, to hold off from supplying rival medicines to its blockbuster Seroxat treatment.
%VIRTUAL-SkimlinksPromo%